Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.37 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | LAP3 | P28838 | 2/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.36 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4041195 | 0.88 | MMP1 (0.41) | VNN1MMP8ACEREN | |
| SCHEMBL4040963 | 0.85 | REN (0.47) | MMP8REN | |
| SCHEMBL3936972 | 0.85 | REN (0.47) | MMP8REN | |
| SCHEMBL4039170 | 0.84 | HPGD (0.41) | MMP8ACE | |
| SCHEMBL4044987 | 0.83 | MMP8 (0.51) | MMP8 | |
| SCHEMBL4039656 | 0.78 | HDAC1 (0.42) | — | |
| SCHEMBL4342649 | 0.76 | SMN1; SMN2 (0.52) | — | |
| SCHEMBL4047233 | 0.75 | CHRND (0.44) | — | |
| SCHEMBL5730463 | 0.75 | REN (0.41) | REN | |
| SCHEMBL4071248 | 0.74 | CYP3A4 (0.50) | VNN1MMP8LAP3ACEANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641801-B9 | BRIDGED N-ARYLSULFONYLPIPERIDINES AS GAMMA-SECRETASE INHIBITORS | SCHERING CORP (US) | 2009-02-25 | — | — | EP | claimed |
| EP-1641801-B1 | BRIDGED N-ARYLSULFONYLPIPERIDINES AS GAMMA-SECRETASE INHIBITORS | SCHERING CORP (US) | 2008-07-16 | — | — | EP | claimed |
| US-7160905-B2 | Hydroxyethylene compounds with Asp2 inhibitory activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-09 | — | — | US | claimed |
| US-20050038028-A1 | Hydroxyethylene compounds with asp2 inhibitory activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-02-17 | — | — | US | claimed |
| EP-1641801-B9 | BRIDGED N-ARYLSULFONYLPIPERIDINES AS GAMMA-SECRETASE INHIBITORS | SCHERING CORP (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1641801-B1 | BRIDGED N-ARYLSULFONYLPIPERIDINES AS GAMMA-SECRETASE INHIBITORS | SCHERING CORP (US) | 2008-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038028-A1 | Hydroxyethylene compounds with asp2 inhibitory activity | BACE2, BACE1, PSEN2 | VNN1 3743/4885MMP8 1094/4885CCKBR 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.